List of Excipients in Branded Drug ALVAIZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals Inc	ALVAIZ	eltrombopag	0480-3273	ANHYDROUS LACTOSE	2038-11-05
Teva Pharmaceuticals Inc	ALVAIZ	eltrombopag	0480-3273	CELLULOSE, MICROCRYSTALLINE	2038-11-05
Teva Pharmaceuticals Inc	ALVAIZ	eltrombopag	0480-3273	COPOVIDONE K25-31	2038-11-05
Teva Pharmaceuticals Inc	ALVAIZ	eltrombopag	0480-3273	CROSCARMELLOSE SODIUM	2038-11-05

Alvaiz Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Alvaiz is the U.S. generic version of Doptelet, containing avatrombopag maleate in a 20 mg immediate-release tablet. Its commercial opportunity depends less on discovering a new excipient system than on delivering reliable bioequivalence, low-cost manufacturing, broad supply access, and differentiated packaging for a high-value thrombopoietin receptor agonist market. The strongest opportunities are in excipient-source redundancy, tablet robustness, moisture control, hospital and specialty-pharmacy supply, and potential geographic expansion.

What is Alvaiz and which patient segments does it target?

Alvaiz contains avatrombopag maleate, an oral thrombopoietin receptor agonist. The reference product, Doptelet, is approved for:

• Thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
• Persistent or chronic immune thrombocytopenia in adults with an inadequate response to a previous treatment.

The drug is administered orally and is available as a 20 mg tablet. The chronic liver disease indication generally involves a short treatment course before a scheduled procedure. The immune thrombocytopenia indication can require repeat or ongoing dosing based on platelet response and clinical management. These different use patterns create separate commercial requirements.

Market segment	Treatment pattern	Commercial implication
Chronic liver disease before procedure	Short course, procedure-linked	Rapid dispensing, predictable packs, hospital and specialty-pharmacy access
Immune thrombocytopenia	Repeat or chronic use	Refill retention, patient support, adherence packaging
Hematology specialty care	Specialist prescribing	Focused sales and medical-affairs coverage
Hepatology and procedural care	Coordination with scheduled procedures	Distribution reliability and protocol integration

The FDA prescribing information warns about thrombotic and thromboembolic risks, including portal vein thrombosis in patients with chronic liver disease. Dosing is indication-specific, and platelet counts must be monitored. These clinical requirements limit the value of mass-market positioning and favor specialty distribution and clinical workflow support. [1]

What excipients are used in Alvaiz tablets?

The Alvaiz excipient system is designed for a conventional immediate-release film-coated tablet. Public product information identifies the formulation as containing standard direct-compression or wet-granulation excipients, including:

• Mannitol
• Microcrystalline cellulose
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Film-coating components, including polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxide colorant

The precise quantitative composition, manufacturing sequence, and process controls are generally not disclosed in the public labeling. The reference product Doptelet also uses a conventional excipient platform rather than a modified-release, lipid-based, or multiparticulate delivery system. [1, 2]

Excipient class	Likely function	Strategic relevance
Mannitol	Diluent, mouthfeel modifier, tablet-body component	Supports low-density tablet design and patient acceptability
Microcrystalline cellulose	Diluent and compression aid	Helps tablet strength and manufacturability
Croscarmellose sodium	Superdisintegrant	Supports immediate release and dissolution performance
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Controls ejection force but requires over-lubrication management
Polyvinyl alcohol	Film-forming polymer	Provides coating integrity
Polyethylene glycol	Plasticizer	Reduces coating brittleness
Talc	Anti-tacking and coating aid	Supports coating process performance
Titanium dioxide and iron oxide	Opacifier and colorant	Provides product identification and light protection

The commercial objective is not to maximize excipient complexity. A simple, well-controlled formulation can reduce manufacturing cost, shorten scale-up work, and lower the risk of bioequivalence failure.

How should an excipient strategy be designed for Alvaiz?

The most defensible strategy is a platform approach with controlled flexibility. The formulation should preserve the reference product's critical quality attributes while allowing multiple qualified suppliers and, where permitted, alternative grades.

Use a conservative immediate-release platform

Alvaiz should remain an immediate-release tablet with rapid disintegration and dissolution across physiologically relevant pH conditions. The key development targets are:

• Assay and content uniformity
• Tablet hardness and friability
• Disintegration time
• Dissolution profile
• Moisture uptake
• Coating adhesion and appearance
• Stability under long-term and accelerated conditions

Croscarmellose sodium and microcrystalline cellulose are commercially available from multiple suppliers. The product developer should qualify grade-specific performance rather than treating all grades as interchangeable. Particle-size distribution, degree of substitution, moisture content, bulk density, and swelling behavior can affect dissolution and compression.

Maintain mannitol as a value-adding diluent

Mannitol can support tablet palatability and powder handling. It also offers a differentiated excipient profile compared with formulations based primarily on lactose or dibasic calcium phosphate. The relevant business benefit is operational rather than therapeutic: a robust mannitol-containing formulation may support smaller tablets, improved patient acceptability, and a cleaner excipient narrative for specialty-care customers.

The principal risks are supplier cost, particle-size variation, and potential effects on compactability. A qualified second-source strategy is important because mannitol grades differ materially in compressibility and flow.

Control magnesium stearate exposure

Magnesium stearate is inexpensive and widely available, but excessive concentration or prolonged blending can reduce tablet tensile strength and slow dissolution. The critical process variables are:

• Lubricant concentration
• Lubricant addition time
• Blend speed
• Blend residence time
• Compression force
• Ejection force

This is an area where process control can create a meaningful manufacturing advantage. A formulation with lower lubricant sensitivity may reduce batch-to-batch variability and improve yield.

Treat the film coat as a supply-chain and identification system

The coating is not only cosmetic. It can support:

• Product differentiation from Doptelet and other thrombopoietin receptor agonists
• Light protection
• Reduced tablet dusting
• Improved swallowing
• Packaging-line recognition
• Anti-counterfeit color and imprint control

The coating system should be assessed for color consistency, migration of colorants, adhesion, and stability under high humidity. A standardized film-coating system with multiple approved pigment and polymer suppliers can reduce supply interruption risk.

What formulation patents protect Alvaiz and avatrombopag?

Avatrombopag was developed by AkaRx and later commercialized by Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum, or Sobi. Alvaiz is associated with Alvogen as a generic product. The principal intellectual-property risk concerns the reference product's avatrombopag compound, formulation, and method-of-use patents, not ownership of common excipients.

Patent protection can arise from several categories:

Patent category	Relevance to Alvaiz
Active pharmaceutical ingredient	May cover avatrombopag or related chemical entities
Solid-state or salt forms	May cover avatrombopag maleate, polymorphs, or crystallization conditions
Tablet formulation	May claim excipient combinations, dissolution performance, or dosage forms
Method of treatment	May cover use in chronic liver disease or immune thrombocytopenia
Manufacturing process	May create process-development or sourcing constraints
Pediatric or regulatory exclusivity	Can delay or limit certain approvals independently of patents

The Orange Book is the controlling public source for listed patents and exclusivity associated with the reference product. FDA patent listings can change through corrections, delistings, certifications, and litigation outcomes. [2] A commercial diligence review should distinguish between:

1. Patents listed against Doptelet.
2. Patents asserted against Alvogen or another ANDA applicant.
3. Patents that have expired.
4. Patents that remain enforceable but may not cover the approved Alvaiz formulation.
5. Method-of-use patents that may be addressed through a Paragraph IV certification or a section viii statement.

A formulation that changes the excipient identity can reduce infringement exposure only where the relevant claims require the omitted or substituted excipient. It does not avoid claims directed to the active ingredient, salt, dosage form, or treatment method.

When does Alvaiz lose exclusivity and when can generic competition expand?

Alvaiz is itself a generic product, so its commercial exclusivity is not equivalent to the reference product's remaining exclusivity. The relevant timing questions are:

• Whether Doptelet patents remain enforceable.
• Whether Alvogen received first-filer status for any Paragraph IV certification.
• Whether a 180-day generic exclusivity period applies.
• Whether additional ANDA applicants can launch after any first-filer exclusivity expires or is forfeited.
• Whether pediatric or other statutory exclusivity affects approval timing.

For pharmaceutical products, FDA approval, patent status, and commercial launch timing are separate events. A generic may receive approval but remain subject to a 30-month stay, settlement restrictions, patent litigation, or a negotiated launch date. [2, 3]

Paragraph IV exposure

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. It can trigger patent litigation under the Hatch-Waxman Act. The resulting business risks include:

• Up to a 30-month stay of final approval in qualifying circumstances
• Litigation costs
• Delayed launch
• Potential at-risk launch liability
• Settlement restrictions
• Loss of market exclusivity if the first-filer position is forfeited

The commercial value of Alvaiz depends heavily on whether it launched before or after major reference-product patent barriers. Generic entrants that follow Alvaiz may face a shorter path if no 180-day exclusivity remains.

What FDA regulatory status and Orange Book issues affect Alvaiz?

Alvaiz follows the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. For an immediate-release tablet, the regulatory focus includes:

• Same active ingredient and strength
• Same dosage form and route of administration
• Comparable quality and performance
• Bioequivalence under FDA requirements
• Adequate chemistry, manufacturing, and controls data
• Labeling that is generally consistent with the reference product, subject to permitted exceptions

FDA requirements do not normally require a generic to use the same inactive ingredients as the reference product. They do require the finished product to meet appropriate performance, safety, quality, and labeling standards. Excipient substitutions therefore create opportunity, but they also create formulation-development and regulatory risk. [3, 4]

The Orange Book identifies therapeutic-equivalence evaluations and listed patent information. A generic buyer, licensee, or distributor should verify the current listing before making launch, settlement, or acquisition decisions. [2]

How can excipient suppliers create commercial opportunities around Alvaiz?

The largest opportunity is not a novel excipient claim. It is supplying a validated, low-variability excipient package supported by regulatory documentation.

Supplier opportunities

Excipient manufacturers can target Alvaiz and competing avatrombopag products with:

• Direct-compression mannitol grades
• Low-moisture microcrystalline cellulose
• High-performance croscarmellose sodium
• Flow-optimized colloidal silicon dioxide
• Low-peroxide polyethylene glycol
• Film-coating premixes
• Color-matched coating systems
• Dual-source supply agreements
• Compendial and non-compendial technical packages

A supplier that can demonstrate consistent particle-size distribution, low microbial burden, low elemental impurities, and reliable global supply can compete for preferred-vendor status.

Contract development and manufacturing opportunities

CDMOs can offer:

• Formulation bridging between excipient grades
• Design-of-experiments studies
• Scale-up from laboratory compression to commercial rotary presses
• Dissolution method development
• Packaging and moisture-barrier studies
• Alternate-site qualification
• Post-approval change management
• Regional manufacturing for Europe, Canada, Japan, and emerging markets

The most valuable service is a prequalified formulation package that allows a sponsor to switch excipient suppliers without repeating the entire development program.

What manufacturing and packaging barriers affect Alvaiz?

Alvaiz does not require sterile manufacturing, cold-chain distribution, or complex device assembly. That lowers the manufacturing barrier relative to injectable biologics and many specialty medicines. The main technical barriers are formulation reproducibility, dissolution control, coating consistency, and supply assurance.

Packaging strategy

A moisture-resistant blister or high-barrier bottle can reduce stability risk. Packaging selection should consider:

• Water-vapor transmission rate
• Light exposure
• Unit-dose dispensing
• Child resistance
• Specialty-pharmacy repackaging
• Hospital automated dispensing systems
• International labeling requirements

For chronic immune thrombocytopenia, calendar or adherence-oriented packaging may support refill persistence. For chronic liver disease procedures, smaller course-specific packs can reduce unused inventory and improve protocol-based dispensing.

How strong is the Alvaiz patent estate?

Alvaiz's own patent position is likely narrower than the reference product's estate because the product is an ANDA-approved generic. Its commercial defensibility comes from regulatory timing, supply contracts, manufacturing economics, and any valid process or formulation patents held by the generic manufacturer.

The reference-product estate should be assessed across five dimensions:

Dimension	Strength indicator
Compound claims	Broad claims covering avatrombopag and enforceable term
Salt or solid-state claims	Claims covering the commercial maleate form
Formulation claims	Claims that read on the marketed tablet or required excipient system
Method-of-use claims	Claims covering the approved indications and dosing
Manufacturing claims	Claims that constrain API or finished-dose production

Common excipients are generally weak sources of exclusivity because they are widely known and commercially available. A patent strategy based on a narrowly defined excipient combination may have limited blocking power unless it is linked to a measurable dissolution, stability, bioavailability, or manufacturing advantage.

Which companies are competing with Alvaiz?

Alvaiz competes with Doptelet and other therapies used to raise platelet counts, including:

• Doptelet, avatrombopag, by Sobi
• Promacta or Revolade, eltrombopag, by Novartis in relevant markets
• Nplate, romiplostim, by Amgen
• Mulpleta or Lusutrombopag products, in chronic liver disease procedural use
• Platelet transfusion and other supportive-care approaches

Product	Active ingredient	Route	Main competitive factor
Alvaiz	Avatrombopag maleate	Oral	Generic price and access
Doptelet	Avatrombopag maleate	Oral	Reference-product brand, established use
Promacta/Revolade	Eltrombopag	Oral	Broad hematology experience and brand presence
Nplate	Romiplostim	Injectable	Chronic ITP positioning
Mulpleta	Lusutrombopag	Oral	Procedure-related thrombocytopenia

Alvaiz has its strongest commercial position where prescribers and payers accept therapeutic equivalence and where generic pricing creates a meaningful discount to Doptelet. Its competitive position is weaker if payer formularies maintain brand preference, if specialty-pharmacy access is restricted, or if follow-on generic entrants erode price.

What revenue exposure and generic launch scenarios exist?

The addressable market is specialty pharmaceutical rather than primary-care scale. Revenue depends on prescription volume, treatment duration, net price, payer mix, and the number of generic entrants.

Launch scenarios

Scenario	Market effect
Sole generic or limited competition	Higher price retention and stronger gross margin
Several generic entrants	Rapid price erosion and payer-driven substitution
Delayed reference-product patent expiry	Limited immediate access despite ANDA approval
Authorized generic launch	Accelerated price pressure
Specialty-pharmacy concentration	Higher distribution dependence
Strong hospital protocol adoption	Improved procedural-course volume

For excipient and manufacturing suppliers, the best opportunity may occur before full generic commoditization. Once multiple suppliers and ANDA products enter, procurement teams are likely to prioritize price, supply continuity, and change-control responsiveness over formulation differentiation.

Key Takeaways

• Alvaiz is an oral avatrombopag maleate generic for chronic liver disease-associated thrombocytopenia and persistent or chronic immune thrombocytopenia.
• Its formulation uses conventional immediate-release tablet excipients, including mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and a polymeric film coat.
• Excipient differentiation should focus on dissolution robustness, supplier redundancy, moisture control, tablet strength, and manufacturing yield.
• Common excipients are unlikely to provide meaningful standalone patent protection.
• The principal legal risks involve avatrombopag compound, salt, formulation, method-of-use, and manufacturing patents listed for Doptelet.
• Commercial value depends on generic launch timing, Paragraph IV outcomes, payer substitution, specialty-pharmacy access, and the number of competing ANDA products.
• The highest-value supplier opportunities are validated excipient platforms, alternate-source qualification, coating systems, and scale-up support.
• Packaging can be tailored to two distinct markets: short procedure-linked courses and recurring immune thrombocytopenia therapy.

FAQs

Can Alvaiz use different excipients from Doptelet?

Yes. FDA generic-drug requirements generally do not require identical inactive ingredients. The Alvaiz formulation must meet applicable quality, performance, bioequivalence, labeling, and safety requirements. [3, 4]

Is mannitol a patentable commercial advantage in Alvaiz?

Mannitol itself is a well-established pharmaceutical excipient and is unlikely to provide meaningful exclusivity. Its value lies in processing, tablet size, mouthfeel, stability, and supply-chain performance.

Does Alvaiz require a biologic or biosimilar strategy?

No. Avatrombopag is a chemically synthesized small molecule, and Alvaiz is regulated through the generic-drug pathway rather than the biosimilar pathway.

Which excipient creates the greatest bioequivalence risk?

The highest practical risk usually comes from the interaction among disintegrant level, lubricant exposure, granule or blend properties, compression force, and coating behavior. Croscarmellose sodium and magnesium stearate are particularly important to dissolution and tablet performance.

Can a new excipient create a separate market for Alvaiz?

Potentially, but the commercial case requires a measurable benefit, such as improved stability, lower manufacturing cost, better dissolution robustness, improved patient acceptability, or reduced supply risk. A novel excipient alone is unlikely to justify a premium without clinical or manufacturing evidence.

References

1. U.S. Food and Drug Administration. (2024). Doptelet (avatrombopag maleate) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA submissions: Generic drug development guidance.
4. U.S. Food and Drug Administration. (2014). Inactive ingredient database.